+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Migraine Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026

  • Report

  • 100 Pages
  • December 2020
  • Region: Global
  • Infinium Global Research
  • ID: 5235796
The report on the global migraine drugs market provides qualitative and quantitative analysis for the period from 2018 to 2026. The report predicts the global migraine drugs market to grow with a CAGR of 8.38% % over the forecast period from 2020-2026. The study on the migraine drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026.

The report on the migraine drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global migraine drugs market over the period of 2018 to 2026. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global migraine drugs market over the period of 2018 to 2026. Further, the Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • The Growing Awareness Regarding Migraine and Numerous Options Available for its Treatment

2) Restraints
  • Adverse Effects of Drugs

3) Opportunities
  • Number of Vendors are Planning to Invest in the Migraine Drugs R&D

Research Methodology

A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and others.
5. Websites and publications by research agencies

Segment Covered
The global migraine drugs market is segmented on the basis of therapeutic class, and treatment type.

The Global Migraine Drugs Market by Therapeutic Class
  • Ergot
  • Triptans
  • Others

The Global Migraine Drugs Market by Treatment Type
  • Abortive
  • Abortive Preventive

Company Profiles
The companies covered in the report include
  • GlaxoSmithKline PLC
  • Amgen Inc.
  • ALLERGAN PLC
  • ELI LILY & Company
  • Merck KGaA
  • Amneal Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Neurelis Inc.
  • Pfizer Inc.
  • Zogenix, Inc.

What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the migraine drugs market.
2. Complete coverage of all the segments in the migraine drugs market to analyze the trends, developments in the global market and forecast of market size up to 2026.
3. Comprehensive analysis of the companies operating in the global migraine drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis, and the latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand, and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Migraine Drugs Market Highlights
2.2. Migraine Drugs Market Projection
2.3. Migraine Drugs Market Regional Highlights
3. Global Migraine Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Migraine Drugs Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Therapeutic Class
3.5.2. Growth Matrix Analysis by Treatment Type
3.5.3. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Migraine Drugs Market
4. Migraine Drugs Market Macro Indicator Analysis
5. Global Migraine Drugs Market by Therapeutic Class
5.1. Ergot
5.2. Triptans
5.3. Others
6. Global Migraine Drugs Market by Treatment Type
6.1. Abortive
6.2. Abortive Preventive
7. Global Migraine Drugs Market by Region 2020-2026
7.1. North America
7.1.1. North America Migraine Drugs Market by Therapeutic Class
7.1.2. North America Migraine Drugs Market by Treatment Type
7.1.3. North America Migraine Drugs Market by Country
7.2. Europe
7.2.1. Europe Migraine Drugs Market by Therapeutic Class
7.2.2. Europe Migraine Drugs Market by Treatment Type
7.2.3. Europe Migraine Drugs Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Migraine Drugs Market by Therapeutic Class
7.3.2. Asia-Pacific Migraine Drugs Market by Treatment Type
7.3.3. Asia-Pacific Migraine Drugs Market by Country
7.4. RoW
7.4.1. RoW Migraine Drugs Market by Therapeutic Class
7.4.2. RoW Migraine Drugs Market by Treatment Type
7.4.3. RoW Migraine Drugs Market by Sub-region
8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Migraine Drugs Market
8.2. Companies Profiled
8.2.1. GlaxoSmithKline PLC
8.2.2. Amgen Inc.
8.2.3. ALLERGAN PLC
8.2.4. ELI LILY & Company
8.2.5. Merck KGaA
8.2.6. Amneal Pharmaceuticals Inc.
8.2.7. H. Lundbeck A/S
8.2.8. Neurelis Inc.
8.2.9. Pfizer Inc.
8.2.10. Zogenix, Inc.

Companies Mentioned

  • GlaxoSmithKline PLC
  • Amgen Inc.
  • ALLERGAN PLC
  • ELI LILY & Company
  • Merck KGaA
  • Amneal Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Neurelis Inc.
  • Pfizer Inc.
  • Zogenix, Inc.